PCV13: Effective Against First-Episode CAP in Older Adults

Approval of the novel oral PDE4B inhibitor offers hope to individuals with the rare, chronic, and progressive pulmonary disease for which treatment options are few.

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

Nerandomilast, with a PDUFA date of Q4 2025, leads the potential breakthrough therapies, with inhaled treprostinil and admilparant advancing quickly behind.

In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.

Large US cohort study finds COVID-19 infection increases short-term risk of asthma, allergic rhinitis, and chronic rhinosinusitis, while vaccination lowers these risks.

The US FDA approved brensocatib as the first treatment for non–cystic fibrosis bronchiectasis.